Denali Therapeutics

US · DNLI #2454 by market cap Listed 2017

19.16 -0.12 -0.62%

Live - 5344 symbols - heartbeat 453s ago · 2026-10-08 07:45

Pre-market 19.00 -0.82%

After-hours 19.16 0.00%

Overnight 19.16 0.00%

Market cap: 3.06B
P/E (TTM): -6.75
P/B: 3.67
EPS: -2.97
Div yield: 0.00%
52W pos: 40%

Reader sentiment Are you bullish or bearish on DNLI?

Anonymous reader poll. Unscientific, not investment advice.

About Denali Therapeutics

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Founded: 2013
CEO: Dr. Ryan J. Watts, PhD
Employees: 503
Headquarters: San Francisco, California, United States of America
Fiscal year end: 12-31
Website: denalitherapeutics.com

Company profile

Exchange: US
Symbol: DNLI
Market-cap rank: #2454
Listing date: 2017-12-08
Market cap: 3.06B
Float cap: 2.97B
Shares out: 159.85M
Float shares: 155.09M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 07:45:21 · For reference only, not investment advice and not tailored to your situation.